Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02611908 |
| Title | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Michael Choi |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries |